Gain Therapeutics reports Phase 1b extension: GluSph down 81%, 4.8-pt MDS-UPDRS difference

Gain Therapeutics, Inc.

16 of 19 Part 1 participants continued into 9-month extension; all 16 remain on study at Day 150.
In participants with elevated baseline CSF GluSph, levels dropped an average of 81% after 90 days.
At Day 150, high-baseline GluSph group showed 4.8-point greater improvement in MDS-UPDRS Parts II+III vs low-baseline group.
Unsolicited patient reports: improved smell/taste (4), balance/gait (4), and sleep (3) after 90 days.
Planned Phase 2 will add UPSIT smell test and Opal wearable gait assessments as endpoints.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.